This case series describes the kinetics of humoral deficiency in patients with relapsed refractory multiple myeloma treated with bispecific antibodies, the infectious complications, and response to COVID-19 immunization.

No abstract

No abstract

Background: Despite their remarkable efficacy in metastatic non-small cell lung cancer (NSCLC), EGFR-and ALK-targeted therapies have not been shown to confer any survival benefit in stage III disease, even in subsets of patients with driver mutations. Case Studies: Here, two patients with unresectable stage III NSCLC carrying mutations in the ALK (case 1) and EGFR (case 2) genes are presented. Treatment of the patient carrying an ALK mutation with an ALK inhibitor and the patient carrying an EGFR mutation with an EGFR inhibitor resulted in dramatic and durable responses. Conclusion: These cases demonstrated that ALK or EGFR mutation-positive stage III NSCLC patients can be treated with the corresponding inhibitors. They also highlight the urgent need for prospective data to assess their potential efficacy in order to improve patient outcomes.Despite several important advances in screening and treatment in the past decade, lung cancer remains one of the most common and lethal malignancies worldwide. In the United States, there are an estimated 234,000 new cases each year, with over 154,000 related deaths annually (1). Nonsmall cell lung cancer (NSCLC) comprises 80-85% of all lung cancer diagnoses (2).The management of locally-advanced (stage III) NSCLC remains a controversial topic, despite ongoing efforts to elucidate the optimal treatment approach. Among the

We conclude that in AL, FISH abnormalities are associated with clonal burden. We found no impact of these markers on the type of organ involvement or 1-year survival.